目的 分析北京市各醫(yī)療機(jī)構(gòu)上報(bào)的奈達(dá)鉑不良反應(yīng)報(bào)告,探討其發(fā)生的一般規(guī)律和特點(diǎn),為臨床合理、安全用藥提供參考依據(jù)。方法 收集2017-2022年北京市各醫(yī)療機(jī)構(gòu)上報(bào)的188例奈達(dá)鉑不良反應(yīng)報(bào)告,對(duì)不良反應(yīng)類別、患者性別和年齡、原患疾病和過敏史、用藥情況、發(fā)生時(shí)間、累及器官/系統(tǒng)及主要臨床表現(xiàn)、臨床轉(zhuǎn)歸等進(jìn)行分析。結(jié)果 188例不良反應(yīng)中,男性106例(56.38%),女性82例(43.62%);61~80歲患者不良反應(yīng)發(fā)生率最高,為94例(50.00%);101例不良反應(yīng)(53.72%)發(fā)生在24h內(nèi);不良反應(yīng)累及器官/系統(tǒng)以全身反應(yīng)最多(85例次,33.60%),其次為血液系統(tǒng)、消化系統(tǒng)、呼吸系統(tǒng);不良反應(yīng)痊愈和好轉(zhuǎn)的有181例(96.28%)。結(jié)論 在應(yīng)用奈達(dá)鉑治療前,應(yīng)對(duì)腫瘤患者的基本情況和用藥史等進(jìn)行綜合評(píng)估,制訂合理用藥方案,在給藥過程中防范速發(fā)型不良反應(yīng)的發(fā)生,完成治療后要及時(shí)進(jìn)行相關(guān)實(shí)驗(yàn)室檢查,盡早發(fā)現(xiàn)和干預(yù)遲發(fā)型不良反應(yīng),從而優(yōu)化合理用藥,保障患者用藥安全有效。

Objective To analyse the adverse reaction reports of nedaplatin reported by medical institutions in Beijing, and to discuss the general rules and characteristics of nedaplatin, so as to provide reference for clinical rational and safe drug use. Methods A total of 188 adverse reactions reports of nedaplatin reported by medical institutions in Beijing from 2017 to 2022 were collected, and patients’ adverse reactions category, gender, age, basic diseases and allergy history, drug administration, the occurrence time, involved organs/systems, main clinical manifestations, and clinical outcomes were analyzed statistically. Results Among the 188 adverse reactions, 106 cases were male patients (56.38%) and 82 cases were female patients (43.62%). The incidence of adverse reactions was more common in 61-80 years old patients (94 cases, 50.00%). 101 Cases (53.72%) occurred within 24 h, and the systemic reaction (85 cases, 33.60%) was the main organs/systems involved in adverse reactions, followed by the blood system, digestive system, and respiratory system. The outcomes of 181 cases (96.28%) were cured or improved. Conclusion The basic situation and medication history of tumor patients should be comprehensively evaluated before the use of nedaplatin. A reasonable medication plan should be formulated. The occurrence of acute adverse reactions should be prevented during the infusion process. The relevant laboratory examinations should be carried out timely after treatment. The occurrence of late adverse reactions should be detected and intervened as soon as possible, so as to optimize rational drug use and ensure drug safety of patients.

R979.1

北京市屬醫(yī)院科研培育計(jì)劃(PZ2021025);北京大學(xué)腫瘤醫(yī)院科研基金(2021-26,2022-25)